Benjamin Rolland1, Benoit Trojak2, Mikail Nourredine3, Jérôme Bachellier4, Mathieu Chappuy5, Patrick Bendimerad6, Margaux Kosim7, Peter Hjelmström8, Fadi Meroueh9, Philippe Nubukpo10, Georges Brousse11. 1. Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, 69500, Bron, France; Service d'Addictologie, Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France; INSERM U1028, CNRS UMR 5292, CRNL, Université de Lyon, UCBL1, Bron, France. Electronic address: benjrolland@gmail.com. 2. Service Hospitalo-Universitaire d'Addictologie, CHU de Dijon, Dijon, France; INSERM U1093, UFR Staps, Université de Bourgogne Franche Comté, France. 3. Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, 69500, Bron, France. 4. Service Universitaire d'Addictologie de Tours, CHU Bretonneau, Tours, France. 5. Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, 69500, Bron, France; Service d'Addictologie, Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France. 6. Service d'Addictologie, Groupe Hospitalier de La Rochelle-Ré-Aunis, La Rochelle, France. 7. Consultations de Médecine-Alcoologie PASS, Groupe Hospitalier Pitié Salpêtrière, Paris, France; Camurus SAS, Paris, France. 8. Camurus AB, Ideon Science Park, Lund, Sweden. 9. UCSA, CHU Lapeyronie, Montpellier, France. 10. Service d'Addictologie, Centre Hospitalier Esquirol, Limoges, France; INSERM UMR 1094, Université de Limoges, Limoges, France. 11. Service de Psychiatrie B et d'Addictologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Équipe d'Accueil 7280, Université Clermont Auvergne, Clermont-Ferrand, France.
Abstract
AIM: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France. METHODS: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment. RESULTS: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring ≥7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95 % = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95 % = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95 %CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95 %CI = 1.67-7.69) and craving (aOR = 2.38; 95 %CI = 1.39-4.02) or improving family (aOR = 1.81; 95 %CI = 1.03-3.13) or professional (aOR = 2.22; 95 %CI = 1.43-3.85) recovery. CONCLUSIONS: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
AIM: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France. METHODS: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment. RESULTS: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring ≥7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95 % = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95 % = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95 %CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95 %CI = 1.67-7.69) and craving (aOR = 2.38; 95 %CI = 1.39-4.02) or improving family (aOR = 1.81; 95 %CI = 1.03-3.13) or professional (aOR = 2.22; 95 %CI = 1.43-3.85) recovery. CONCLUSIONS: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
Authors: Salomon Poliwoda; Nazir Noor; Jack S Jenkins; Cain W Stark; Mattie Steib; Jamal Hasoon; Giustino Varrassi; Ivan Urits; Omar Viswanath; Adam M Kaye; Alan D Kaye Journal: Health Psychol Res Date: 2022-08-20
Authors: Gabriel G Edwards; Ayako Miyashita-Ochoa; Enrico G Castillo; David Goodman-Meza; Ippolytos Kalofonos; Raphael J Landovitz; Arleen A Leibowitz; Craig Pulsipher; Ed El Sayed; Steven Shoptaw; Chelsea L Shover; Michelle Tabajonda; Yvonne S Yang; Nina T Harawa Journal: AIDS Behav Date: 2022-09-05